EPC-002

N/A

Report date: 2026/05/21 20:00:22

Base Information

Drug NameEPC-002
Drug Alias NameEPC-002EPC 002EPC002
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > Chimeric antigen receptor γδT cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Gamma delta T-cell therapy > Chimeric antigen receptor γδT cell therapyCell and gene therapy > Cell therapy > Source of cells > Umbilical cord blood-derived
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityCD276 antigen modulators +[5] 
TargetsCD276 antigenInterleukin-2 receptorProgrammed death-ligand 1
Therapy Area/IndicationsSolid tumoursUrinary Bladder NeoplasmsCarcinoma, Non-Small-Cell Lung +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesElpis BioPharmaceuticals Corp
China Registration ClassN/A

Develop Information

Active CompaniesElpis BioPharmaceuticals Corp
Inactive CompaniesN/A
Active IndicationsSolid tumoursUrinary Bladder NeoplasmsCarcinoma, Non-Small-Cell Lung +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A